NEW YORK, Sept. 24, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous ...

A Material Transfer Agreement (MTA) governs the transfer of biological, chemical, archeological and other materials from one organization to another. Usually the materials in question are proprietary ...

Actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the Company’s Annual Report on Form 20-F for the year ended April 30 ...

A Material Transfer Agreement (MTA) is a contract between a provider of a material and the recipient that memorializes the rights and responsibilities regarding research material. It defines who owns ...

Lexaria previously announced, on September 3, 2024, that it had entered into a Material Transfer Agreement ("MTA") with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH TM ...

(2024-10-02 | NDAQ:IPA) ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus. Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of ...

A New York-based biotech company is turning heads on Tuesday after it announced it signed a material transfer agreement to supply SLS-002 for the Department of Defense’s military and veterans ...

3 June 2025 ValiRx PLC ("ValiRx" or the "Company") New Evaluation and Material Transfer Agreement. ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer ...

Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD. PR Newswire .

Lexaria previously announced, on September 3, 2024, that it had entered into a Material Transfer Agreement ("MTA") with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH TM ...

Under this agreement, Biotheus will receive a specialized antibody asset from Talem Therapeutics, a subsidiary of ImmunoPrecise Antibodies. Biotheus plans to use this asset in conjunction with its ...